Huang Huan, Xia Anqi, Sun Li, Lu Chun, Liu Ying, Zhu Zhenjie, Wang Siye, Cai Junyan, Zhou Xiaoyun, Liu Su
Department of Rehabilitation Medicine, Affiliated Hospital of Nantong University, Nantong, China.
School of Medicine, Nantong University, Nantong, China.
Front Mol Neurosci. 2021 Apr 21;14:629910. doi: 10.3389/fnmol.2021.629910. eCollection 2021.
Neuroinflammation contributes to delayed (secondary) neurodegeneration following traumatic brain injury (TBI). Tumor necrosis factor receptor-associated factor 6 (TRAF6) signaling may promote post-TBI neuroinflammation, thereby exacerbating secondary injury. This study investigated the pathogenic functions of TRAF6 signaling following TBI and . A rat TBI model was established by air pressure contusion while lipopolysaccharide (LPS) exposure was used to induce inflammatory-like responses in cultured astrocytes. Model rats were examined for cell-specific expression of TRAF6, NF-κB, phosphorylated (p)-NF-κB, MAPKs (ERK, JNK, and p38), p-MAPKs, chemokines (CCL2 and CXCL1), and chemokine receptors (CCR2 and CXCR2) by immunofluorescence, RT-qPCR, western blotting, and ELISA, for apoptosis by TUNEL staining, and spatial cognition by Morris water maze testing. These measurements were compared between TBI model rats receiving intracerebral injections of TRAF6-targeted RNAi vector (AAV9-TRAF6-RNAi), empty vector, MAPK/NF-κB inhibitors, or vehicle. Primary astrocytes were stimulated with LPS following TRAF6 siRNA or control transfection, and NF-κB, MAPKs, chemokine, and chemokine receptor expression levels evaluated by western blotting and ELISA. TRAF6 was expressed mainly in astrocytes and neurons of injured cortex, peaking 3 days post-TBI. Knockdown by AAV9-TRAF6-RNAi improved spatial learning and memory, decreased TUNEL-positive cell number in injured cortex, and downregulated expression levels of p-NF-κB, p-ERK, p-JNK, p-p38, CCL2, CCR2, CXCL1, and CXCR2 post-TBI. Inhibitors of NF-κB, ERK, JNK, and p38 significantly suppressed CCL2, CCR2, CXCL1, and CXCR2 expression following TBI. Furthermore, TRAF6-siRNA inhibited LPS-induced NF-κB, ERK, JNK, p38, CCL2, and CXCL1 upregulation in cultured astrocytes. Targeting TRAF6-MAPKs/NF-κB-chemokine signaling pathways may provide a novel therapeutic approach for reducing post-TBI neuroinflammation and concomitant secondary injury.
神经炎症会导致创伤性脑损伤(TBI)后的延迟性(继发性)神经退行性变。肿瘤坏死因子受体相关因子6(TRAF6)信号传导可能会促进TBI后的神经炎症,从而加剧继发性损伤。本研究调查了TBI后TRAF6信号传导的致病作用。通过气压挫伤建立大鼠TBI模型,同时使用脂多糖(LPS)暴露诱导培养的星形胶质细胞产生炎症样反应。通过免疫荧光、RT-qPCR、蛋白质印迹和酶联免疫吸附测定法检测模型大鼠中TRAF6、核因子κB(NF-κB)、磷酸化(p)-NF-κB、丝裂原活化蛋白激酶(MAPKs,即细胞外信号调节激酶ERK、应激活化蛋白激酶JNK和p38)、p-MAPKs、趋化因子(CCL2和CXCL1)以及趋化因子受体(CCR2和CXCR2)的细胞特异性表达,通过TUNEL染色检测细胞凋亡情况,并通过莫里斯水迷宫试验检测空间认知能力。对接受脑内注射TRAF6靶向RNA干扰载体(AAV9-TRAF6-RNAi)、空载体、MAPK/NF-κB抑制剂或溶剂的TBI模型大鼠进行上述测量并比较。在TRAF6小干扰RNA(siRNA)或对照转染后,用LPS刺激原代星形胶质细胞,并通过蛋白质印迹和酶联免疫吸附测定法评估NF-κB、MAPKs、趋化因子和趋化因子受体的表达水平。TRAF6主要在受伤皮质的星形胶质细胞和神经元中表达,在TBI后3天达到峰值。AAV9-TRAF6-RNAi敲低可改善空间学习和记忆能力,减少受伤皮质中TUNEL阳性细胞数量,并下调TBI后p-NF-κB、p-ERK、p-JNK、p-p38、CCL2、CCR2、CXCL1和CXCR2的表达水平。NF-κB、ERK、JNK和p38的抑制剂可显著抑制TBI后CCL2、CCR2、CXCL1和CXCR2的表达。此外,TRAF6-siRNA可抑制LPS诱导的培养星形胶质细胞中NF-κB、ERK、JNK、p38、CCL2和CXCL1的上调。靶向TRAF6-MAPKs/NF-κB-趋化因子信号通路可能为减轻TBI后的神经炎症及伴随的继发性损伤提供一种新的治疗方法。